Bio-techne Corp (TECH): Roger C Lucas , director of Bio-techne Corp sold 100 shares on Sep 21, 2016. The Insider selling transaction was reported by the company on Sep 23, 2016 to the Securities and Exchange Commission. The shares were sold at $108.91 per share for a total value of $10,891.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 12, 2016, Kevin S Gould (SVP Clinical Controls) sold 524 shares at $110.50 per share price.On Sep 12, 2016, John L Higgins (director) sold 1,700 shares at $109.83 per share price.Also, On Sep 6, 2016, Robert V Baumgartner (director) sold 6,467 shares at $107.16 per share price.On Aug 19, 2016, Roger C Lucas (director) sold 100 shares at $113.70 per share price.
BIO-TECHNE Corp: On Thursday, Sep 22, 2016 heightened volatility was witnessed in BIO-TECHNE Corp which led to swings in the share price. The shares opened for trading at $107.76 and hit $109.66 on the upside , eventually ending the session at $109.51, with a gain of 1.88% or 2.02 points. The heightened volatility saw the trading volume jump to 1,57,764 shares. The 52-week high of the share price is $117.42 and the company has a market cap of $4,084 M . The 52-week low of the share price is at $79.95.
Bio-Techne Corporation (Bio-Techne) formerly Techne Corporation develops manufactures and sells biotechnology reagents instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins including cytokines and growth factors antibodies related immunoassays biologically active small molecules and other reagents to the research diagnostics and clinical controls markets.